News from NORD

Foundation Fighting Blindness Opens USH2A Natural History Study


 

The first patient has been enrolled in a four-year, 120-person study of the rate of disease progression and severity in people with mutations in the USH2A gene, a mutation that causes blindness and in some cases the loss of both vision and hearing. Additional information is available here.

Recommended Reading

VIDEO: Triple therapy study and new recommendations provide guidance on CAPS
MDedge Hematology and Oncology
Eribulin superior to dacarbazine in advanced liposarcoma
MDedge Hematology and Oncology
Join the National Organization for Rare Disorders and the University of Massachusetts for Two Upcoming CME-Accredited Events
MDedge Hematology and Oncology
Rare Disease Film Festival Is Planned
MDedge Hematology and Oncology
NORD Outlines Recommendations for Health Care Reform in Letter to Congressional Leadership
MDedge Hematology and Oncology
Alport Syndrome Research Funding Is Awarded
MDedge Hematology and Oncology
Aplastic Anemia and MDS International Foundation Plans Regional Patient/Family Conference
MDedge Hematology and Oncology
Global CMTC/OVM Conference to Take Place in The Netherlands
MDedge Hematology and Oncology
Conan O’Brien to Host Congenital Hyperinsulinism International Event
MDedge Hematology and Oncology
CurePSP International Research Symposium to Take Place in San Francisco
MDedge Hematology and Oncology